{"id":"W4403673251","doi":"10.1212/nxi.0000000000200328","title":"Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies","year":2024,"lang":"en","type":"article","venue":"Neurology Neuroimmunology & Neuroinflammation","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Health and Medical Research Council; Sanofi Genzyme; Mitsubishi Tanabe Pharma Corporation; Fondation Charcot; Univerzita Karlova v Praze; Karadeniz Teknik Üniversitesi; Eisai; Sanofi; Multiple Sclerosis International Federation; Canadian Institutes of Health Research; Fonds Wetenschappelijk Onderzoek; Murdoch University; Multiple Sclerosis Australia; Multiple Sclerosis Society; Multiple Sclerosis Society of Canada; Všeobecná Fakultní Nemocnice v Praze; Biogen; Celgene; Hunter New England Local Health District; Sveučilište u Zagrebu; F. Hoffmann-La Roche; Medicinski Fakultet, Sveučilište u Zagrebu; Monash University; Alexion Pharmaceuticals; Vlaamse regering; National Multiple Sclerosis Society; Amicus Therapeutics; Medical Research Council; Teva Pharmaceutical Industries; Novartis Pharma; European Commission","keywords":"Ocrelizumab; Medicine; Disease; Multiple sclerosis; Pregnancy; Internal medicine; Immunology; Rituximab","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002912134,0.0004908724,0.0006117688,0.0006764677,0.0002807325,0.0001153391,0.0001995298,0.0001516162,0.00008048707],"category_scores_gemma":[0.001191687,0.0003690762,0.00007830577,0.0005702291,0.0007009532,0.0005168367,0.0002765546,0.001096832,0.00003064898],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001011999,"about_ca_system_score_gemma":0.0002779325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005472702,"about_ca_topic_score_gemma":0.0001328559,"domain_scores_codex":[0.9962444,0.0007466749,0.0004618079,0.001204338,0.0003966828,0.0009460651],"domain_scores_gemma":[0.9974853,0.001288341,0.0001309364,0.0006935761,0.0000948708,0.0003069962],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.09761424,0.0007192871,0.3660018,0.001689552,0.0004234945,0.004929312,0.00331519,0.0002618431,0.4358203,0.0001450831,0.0001092439,0.08897058],"study_design_scores_gemma":[0.002831597,0.001951839,0.9828644,0.0005374074,0.00006664871,0.0001447417,0.00004231565,0.009503207,0.0005414764,0.00006233784,0.001176811,0.000277162],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9793283,0.001650502,0.00003440413,0.01669299,0.0002741455,0.00149223,0.00003730188,0.0004317062,0.00005839701],"genre_scores_gemma":[0.9931541,0.005248492,0.00003793842,0.0006685093,0.00009378607,0.0005275646,0.00001164165,0.0001239843,0.0001340033],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6168627,"threshold_uncertainty_score":0.9998761,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04454560062272642,"score_gpt":0.2798303811565144,"score_spread":0.235284780533788,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}